>> In other words there is no miracle drug out there to affect a change in the FDA's three year stance. <<
Diabetic retinopathy/DME progresses more slowly than AMD –hence the FDA’s requirement for three-year data to support an approval. Shorter trials might be possible if there were reliable surrogate markers, but none have yet been found that correlate to the permanent change in visual acuity.
>> What treatment options are available for DME? <<
The thermal laser, provided that the lesion is not located in the foveal (central) region.
Market Data 
Markets 
AI
